Creating a Brighter Future Together – NICTN and the NI Cancer Research Consumer Forum Celebrate Cancer Research and PPI at Event to Launch new PPI Strategy

The NI Cancer Trials Network (NICTN) and NI Cancer Research Consumer Forum (NICRCF) wish to thank everyone involved and all who joined them at their new Personal and Public Involvement (PPI) Strategy launch event 26 March 2019 in the Belfast City Hospital.

While looking ahead to the future, the event was also a celebration of current local cancer research and successful partnership working. Margaret Grayson (NICRCF Chairperson) welcomed everyone and Margaret and Ruth Boyd (CRUK Senior Nurse and NICTN/ECMC PPI Professional Lead) kicked-off the presentations with a profile of PPI, an overview of the work of the NICRCF and a review of the new strategy’s goals.  The goals are to:

  • further embed a culture of partnership working in cancer research
  • provide sustainable support for the NICRCF to enable PPI in cancer research to grow
  • maximise the impact of PPI through best practice and standards

 

The strategy is now out for consultation until the end of June 2019 – all comments are very welcome!

The agenda for the afternoon also covered developments in treatment and care across a range of cancers.

Mr Stuart McIntosh (Clinical Senior Lecturer, QUB, Consultant Breast Surgeon, Belfast Trust, Acting Clinical Director NICTN) explained that clinical trials were available across Northern Ireland, co-ordinated by the NICTN. Stuart explained that within breast cancer research there were several themes that were evident:

  • de-escalation of treatment – to minimise unnecessary side-effects
  • precision – to ensure treatment is tailored to an individual’s specific tumour
  • increasing collaboration across professionals and including patient representation
  • increasing patient expectation to receive clinical research options as part of standard practice
  • During a refreshment break the 85 people attending the event, from across Trusts, universities, charities, patients and public, had the opportunity to access information from a number of services, charities and research funders, alongside information from the NICTN and NICRCF. We are very grateful for the information stands and representatives of:
  • NICRCF members Hazel Carson (BRCA Link NI and CIBRAC study Trial Management Group) and Dr Sandra Irvine, PPI representative in regional and national bowel cancer research groups, joined Stuart and Philip on a panel during a Q&A session. Members of the audience asked questions leading to discussion about bowel cancer screening availability, the role of a PPI representative, national developments in bowel cancer research and breast cancer trials.
  • Dr Philip Dunne (Lecturer in Early Cancer Detection, Centre for Cancer Research and Cell Biology, Queen’s University Belfast) outlined the development of bowel cancer at tumour and cellular levels, highlighting how molecular profiling of tissue in the laboratory is enabling the development of personalised treatment. Biomarkers can help to predict an individual’s sensitivity to particular treatment, helping doctors select treatments for patients with most benefit and fewer side-effects. Philip also emphasised the value of bowel cancer screening in early detection.
  • A number of studies were outlined in the settings of prevention, ductal carcinoma in-situ, early invasive breast cancer, post-operative radiotherapy and chemotherapy before surgery. Stuart advocated the value of patient representative membership in the study management groups for the trials he was leading on.
  • HSC R&D
  • NI Biobank
  • Friends of the Cancer Centre
  • OGCancerNI
  • Leukaemia and Lymphoma NI
  • Belfast Trust PPI
  • Macmillan Information and Support Centre
  • Cancer Research UK

Dr Ciaran Fairmichael (Clinical Research Fellow, QUB, ST6 Clinical Oncology Doctor, NI Cancer Centre, Belfast Trust) provided an encouraging overview of how local cancer trials were having a positive impact on outcomes for men with prostate cancer. Ciaran described early results from the ADRRAD and SPORT trials and explained how these treatment advances are transforming care in Northern Ireland.

NICRCF member Kate Burns was the next speaker. Kate provided a very moving and eloquent personal insight into her husband Paul’s experience of life with prostate cancer until, sadly, Paul died in 2014.  Kate described the transition of ‘person to patient’ and the significance of holistic care throughout treatment, research and palliative care.  Paul had shared his story at a NICRCF public event back in 2012, so the NICTN/NICRCF were particularly delighted and humbled that Kate spoke at this event.

Dr Olinda Santin concluded the presentations with an honest and enjoyable description of the valuable impact involvement of NICRCF members had on a project to develop support for carers. Through these discussions the project changed direction, resulting in the development of a website, designed with and for carers.  This website ‘Cancer Caring Coping’ has already been adopted internationally and provides a unique and accessible resource for carers.

The event concluded with a final Q&A panel, where Ciaran, Kate and Olinda were joined by NICRCF members Ken McBride and NICTN Operational Director Dr Melanie Morris. Melanie thanked speakers and along with Kate highlighted how valuable the carer website would be. Questions from the audience lead to discussion about treatments for prostate cancer available in Northern Ireland, and Ken described why he had taken the decision to participate in a clinical trial.

Margaret concluded the event and many attendees took copies or summaries of ‘A Strategy for PPI in Cancer Research in Northern Ireland’ or other information.

The NICTN and NICRCF were delighted with the positive reaction of the audience to the event. Comments received included:

  • Fascinating to learn about scope of clinical research in NI & hear from doctors, patients and other affected people
  • High quality of the presentations and guest speakers
  • Patient story was really helpful in understanding contribution & PPI modifying research
  • Kate Burns’ talk was very moving- an inspirational representative for the forum
  • Olinda’s website is incredibly useful
  • Current prostate cancer research very informative and the emphasis on carer resources
  • Evaluation was also unanimously positive, frequently describing the event as excellent.

 

Some Speakers and Panel Members (Lt-Rt) Back Row: Mr Stuart McIntosh (BHSCT/QUB), Dr Philip Dunne (QUB) Front Row: NICRCF members – Kate Burns, Sandra Irvine, Margaret Grayson, Hazel Carson and Dr Olinda Santin (QUB)

 

Speakers Dr Olinda Santin (QUB) and Dr Ciaran Fairmichael (BHSCT/QUB)

 

 

 

 

 

 

 

 

 

 

 

Click the links below for more pictures fom our event!

Strategy event pictures 1 

Strategy event pictures 2

 

 

 

 

 

 

Tuesday 26th March ‘Cancer Research in Northern Ireland: Creating a Brighter Future Together’

Public Information Event ‘Cancer Research in Northern Ireland: Creating a Brighter Future Together’

Join the Northern Ireland Cancer Trials Network and Northern Ireland Cancer Research Consumer Forum in a celebration of Personal & Public Involvement (PPI) in research and local research success. A new strategy for PPI in Cancer Research will be launched at this event. Please see flyer below for more details.

Contact Amy at 028 9063 8468 for registration.

All welcome!

Click to enlarge^

Click this link to see the finalised agenda

 

 

 

 

 

 

 

 

 

 

 

 

‘Extending the Reach of Partnership’ – Annual Report published on website

 ‘Extending the Reach of Partnership’ – Annual Report published on website

The NI Cancer Research Consumer Forum and NICTN are pleased to announce the Forum’s 2015/2016 annual report is now available on the website (to view the report simply click on this  link ). We hope you enjoy this review of a very active year for the Forum.  As always, we welcome your comments and feedback.

 

ADRRAD prostate cancer trial patient tells his story – see video

Click on the link to ‘David’s Story’ and scroll down to see a short video featuring Mr David Livingstone speaking about his participation in the ADRRAD study.  ADRRAD [Neo-adjuvant Androgen Deprivation Therapy, Pelvic Radiotherapy and RADium-223 for new presentation T1-4 N0/1 M1B adenocarcinoma of prostate] is a clinical trial led by Professor Joe O’Sullivan, Queen’s University Belfast (QUB) / NI Cancer Centre.  In this Movember video Professor O’Sullivan describes the research endeavour to develop new ways to help men with advanced prostate cancer.  The ADRRAD study is co-ordinated by the NI Cancer Trials Network/Belfast Experimental Cancer Medicine Centre, and recruitment is nearing completion.  The NICTN and the team of doctors, research radiographers and Trust and University staff involved wish to thank all the men like David who are taking part in this study. 

The study is sponsored by Belfast HSC Trust and funded by Bayer PLC and the Friends of the Cancer Centre.

 

 

 

Dr Ciaran Fairmichael win’s first prize for SPORT study presentation

Dr Ciaran Fairmichael

The Queen’s University School of Medicine, Dentistry and Biomedical Sciences Postgraduate Research Forum was on 9th November at Riddel Hall. The early results from the SPORT trial were presented by Dr Ciaran Fairmichael as a poster which was selected for oral presentation and went on to win 1st prize. The poster describes the early results from the trial which is co-ordinated by the NICTN. The results presented suggest there is benefit in combining stereotactic prostate radiotherapy, a technique that allows delivery of prostate radiotherapy in only 5 treatments instead of the usual 20-37 days of treatment, with an injected spacer gel to protect the lower bowel. Translational work within the trial looking at blood biomarkers to test for early signs of radiation toxicity was also presented.

Congratulations Ciaran!

Ed Goodall reports from ESMO

Dr. Ed Goodall

Northern Ireland Cancer Research Forum (NICRCF) member, Ed Goodall, was elected in 2018 to the Patient Advisory Committee (PAC) of the Europacolon organisation which incorporates researchers and healthcare professionals from nearly 40 countries. They held their recent October meeting in Munich in conjunction with ESMO (The European Society for Medical Oncology) at the MesseGrande Conference Centre, constructed on the site of the old Oberwiesenfeld airport.

Angel of Peace

 

A main focus of the meeting was the strategic use of Biosimilars which companies are allowed to make when the patent of the original medicine expires. They are usually able to produce and sell the Biosimilar more cheaply than the original reference medicines. Thus, they are appealing for Healthcare systems and may help to improve access to important medicines for cancer patients and, in particular, for those with metastatic colorectal cancer. A further important discussion concentrated on a strategic policy in Europe for routine screening and the optimal age at which it should be offered. The consensus appeared to be at 50 years of age and supported by more informative publicity campaigns which had been successful in some EC countries. In conclusion, Ed Goodall commented, ‘I left Munich, its Chocolate Box Centre dominated by the golden statuette of the Angel of Peace pointing heavenwards, buzzing with new ideas and inspired to renew efforts to finally defeat our old enemy, cancer.’

 

 

Belfast Top UK Recruiter to DARS

Belfast Trust was the top UK recruiter to DARS (A phase III randomised multicentre study of dysphagia optimised intensity modulated radiotherapy (DoIMRT) versus standard intensity modulated radiotherapy (SIMRT) in head and neck cancer.)  Belfast recruitment was above the original local target and the site was commended by the study co-ordinator.  Dr Keith Rooney, the local Principal Investigator, acknowledged how excellent team work had contributed to local success.  We wish to thank all the patients taking part in this study.

Karen Parsons – Finalist – RCNi Excellence in Cancer Research Award – London

Karen Parsons – Finalist RCNi Excellence in Cancer Research Award, London 04 July 2018

The NICTN team and other colleagues congratulated Karen Parsons on her success, reaching the final of the 2018 RCNi Nursing Awards. Karen was one of just five UK finalists in the Excellence in Cancer Research Award category, sponsored by Cancer Research UK. The ceremony was held in the Westminster Park Plaza Hotel in London 04 July 2018.  The event was a celebration of excellence in nursing across a range of healthcare settings and gave recognition to the amazing work of individuals and teams.

The RCNi summarised Karen’s Prostate Cancer UK funded project achievement: ‘Karen conducted a pilot project integrating holistic needs assessments (HNAs) into the role of cancer research nurses when they become the key workers for prostate cancer patients participating in clinical trials. The HNA includes assessment of physical, practical, family/relationship, emotional, spiritual/religious concerns and lifestyle or information needs. The process includes continence and erectile dysfunction assessment, and development of appropriate care plans and referral. As well as ensuring seamless patient care, a care plan is devised with the patient agreeing the best way to manage concerns or appropriate referrals are made. Positive feedback indicates high levels of satisfaction with information, contact, treatment and support.’

Ruth Boyd, Cancer Research UK Senior Nurse in NI, also attended the awards, and was privileged to present the award to the winner of the Excellence in Cancer Research Award category.

Karen Parsons (Finalist) and Ruth Boyd – RCNi Nurse Awards, London 04 July 2018